Jeremy C. Flinders

Array ( [id] => 10679572 [patent_doc_number] => 20160025717 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-01-28 [patent_title] => 'HYPOSIALYLATION DISORDERS' [patent_app_type] => utility [patent_app_number] => 14/775507 [patent_app_country] => US [patent_app_date] => 2014-03-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 10 [patent_figures_cnt] => 10 [patent_no_of_words] => 20500 [patent_no_of_claims] => 29 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14775507 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9735903 [patent_doc_number] => 20140271615 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2014-09-18 [patent_title] => 'HYPOSIALYLATION DISORDERS' [patent_app_type] => utility [patent_app_number] => 14/208570 [patent_app_country] => US [patent_app_date] => 2014-03-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 10 [patent_figures_cnt] => 10 [patent_no_of_words] => 19961 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14208570 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9735916 [patent_doc_number] => 20140271628 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2014-09-18 [patent_title] => 'HUMANIZED, ANTI-N2 ANTIBODIES' [patent_app_type] => utility [patent_app_number] => 14/206368 [patent_app_country] => US [patent_app_date] => 2014-03-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 11 [patent_figures_cnt] => 11 [patent_no_of_words] => 14770 [patent_no_of_claims] => 36 [patent_no_of_ind_claims] => 5 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14206368 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10573102 [patent_doc_number] => 09295724 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2016-03-29 [patent_title] => 'Stable formulations for parenteral injection of peptide drugs' [patent_app_type] => utility [patent_app_number] => 14/192679 [patent_app_country] => US [patent_app_date] => 2014-02-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 2 [patent_figures_cnt] => 2 [patent_no_of_words] => 19658 [patent_no_of_claims] => 27 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 91 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14192679 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10620617 [patent_doc_number] => 09339545 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2016-05-17 [patent_title] => 'Stable formulations for parenteral injection of peptide drugs' [patent_app_type] => utility [patent_app_number] => 14/192697 [patent_app_country] => US [patent_app_date] => 2014-02-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 2 [patent_figures_cnt] => 2 [patent_no_of_words] => 19618 [patent_no_of_claims] => 27 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 98 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14192697 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10579898 [patent_doc_number] => 09302010 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2016-04-05 [patent_title] => 'Stable formulations for parenteral injection of peptide drugs' [patent_app_type] => utility [patent_app_number] => 14/188464 [patent_app_country] => US [patent_app_date] => 2014-02-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 2 [patent_figures_cnt] => 2 [patent_no_of_words] => 19617 [patent_no_of_claims] => 19 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 79 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14188464 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9670998 [patent_doc_number] => 20140234861 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2014-08-21 [patent_title] => 'METHOD FOR DIAGNOSIS, PROGNOSIS OR TREATMENT OF ACUTE CORONARY SYNDROME (ACS) COMPRISING MEASUREMENT OF PLASMA CONCENTRATION OF MACROPHAGE MIGRATION INHIBITORY FACTOR (MIF)' [patent_app_type] => utility [patent_app_number] => 14/178660 [patent_app_country] => US [patent_app_date] => 2014-02-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 5 [patent_figures_cnt] => 5 [patent_no_of_words] => 9948 [patent_no_of_claims] => 25 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14178660 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9615755 [patent_doc_number] => 20140205613 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2014-07-24 [patent_title] => 'ANTI-TNF AND ANTI-IL 17 COMBINATION THERAPY BIOMARKERS FOR INFLAMMATORY DISEASE' [patent_app_type] => utility [patent_app_number] => 14/160253 [patent_app_country] => US [patent_app_date] => 2014-01-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 13 [patent_figures_cnt] => 13 [patent_no_of_words] => 17089 [patent_no_of_claims] => 96 [patent_no_of_ind_claims] => 11 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14160253 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9511891 [patent_doc_number] => 20140148383 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2014-05-29 [patent_title] => 'Entacapone for prevention and treatment of obesity and related metabolic diseases' [patent_app_type] => utility [patent_app_number] => 14/147531 [patent_app_country] => US [patent_app_date] => 2014-01-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 5 [patent_figures_cnt] => 5 [patent_no_of_words] => 4330 [patent_no_of_claims] => 21 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14147531 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9560682 [patent_doc_number] => 20140178395 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2014-06-26 [patent_title] => 'TREATMENT OF NEPHROPATHY' [patent_app_type] => utility [patent_app_number] => 14/135921 [patent_app_country] => US [patent_app_date] => 2013-12-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 11 [patent_figures_cnt] => 11 [patent_no_of_words] => 9738 [patent_no_of_claims] => 15 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14135921 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9634323 [patent_doc_number] => 20140212431 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2014-07-31 [patent_title] => 'PCSK9-BINDING POLYPEPTIDES AND METHODS OF USE' [patent_app_type] => utility [patent_app_number] => 14/133986 [patent_app_country] => US [patent_app_date] => 2013-12-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 9 [patent_figures_cnt] => 9 [patent_no_of_words] => 13379 [patent_no_of_claims] => 27 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14133986 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9546975 [patent_doc_number] => 20140171624 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2014-06-19 [patent_title] => 'MODULATORS OF ADP-DEPENDENT GLUCOKINASE (ADPGK) AND GLYCEROL-3-PHOSPHATE DEHYDROGENASE (GPD2) FOR THERAPY' [patent_app_type] => utility [patent_app_number] => 14/099466 [patent_app_country] => US [patent_app_date] => 2013-12-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 37 [patent_figures_cnt] => 37 [patent_no_of_words] => 16475 [patent_no_of_claims] => 15 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14099466 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9517770 [patent_doc_number] => 20140154263 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2014-06-05 [patent_title] => 'Use of TAK1 Inhibitor to Achieve Glycemic Control in Mammals' [patent_app_type] => utility [patent_app_number] => 14/097967 [patent_app_country] => US [patent_app_date] => 2013-12-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 33 [patent_figures_cnt] => 33 [patent_no_of_words] => 5779 [patent_no_of_claims] => 11 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14097967 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10946294 [patent_doc_number] => 20140349316 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2014-11-27 [patent_title] => 'USE OF TUMOR NECROSIS FACTOR (TNF) RECEPTOR-ASSOCIATED FACTOR 7 (TRAF7) AS BIOMARKER FOR SYSTEMIC LUPUS ERYTHEMATOSUS (SLE), METHOD AND KIT FOR DETECTING OF HUMAN WITH SLE' [patent_app_type] => utility [patent_app_number] => 14/091325 [patent_app_country] => US [patent_app_date] => 2013-11-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 4 [patent_figures_cnt] => 4 [patent_no_of_words] => 2728 [patent_no_of_claims] => 8 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14091325 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10149260 [patent_doc_number] => 09181538 [patent_country] => US [patent_kind] => B1 [patent_issue_date] => 2015-11-10 [patent_title] => 'Kexin-based vaccines to prevent or treat fungal infections' [patent_app_type] => utility [patent_app_number] => 14/088250 [patent_app_country] => US [patent_app_date] => 2013-11-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 5 [patent_figures_cnt] => 7 [patent_no_of_words] => 21708 [patent_no_of_claims] => 13 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 33 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14088250 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9369846 [patent_doc_number] => 20140079719 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2014-03-20 [patent_title] => 'IL-17 Antagonistic Antibodies' [patent_app_type] => utility [patent_app_number] => 14/085074 [patent_app_country] => US [patent_app_date] => 2013-11-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 3 [patent_figures_cnt] => 3 [patent_no_of_words] => 19088 [patent_no_of_claims] => 11 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14085074 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15540867 [patent_doc_number] => 10570199 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2020-02-25 [patent_title] => Human antibody against IL-18 [patent_app_type] => utility [patent_app_number] => 14/442004 [patent_app_country] => US [patent_app_date] => 2013-11-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 8 [patent_figures_cnt] => 8 [patent_no_of_words] => 17873 [patent_no_of_claims] => 17 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 105 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14442004 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13182703 [patent_doc_number] => 10106855 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2018-10-23 [patent_title] => Genetic assay to determine prognosis in Polycythemia Vera patients [patent_app_type] => utility [patent_app_number] => 14/441721 [patent_app_country] => US [patent_app_date] => 2013-11-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 12 [patent_figures_cnt] => 16 [patent_no_of_words] => 43403 [patent_no_of_claims] => 15 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 224 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14441721 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9330143 [patent_doc_number] => 20140056925 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2014-02-27 [patent_title] => 'Methods of Reducing Myocardial Injury Following Myocardial Infarction' [patent_app_type] => utility [patent_app_number] => 14/073386 [patent_app_country] => US [patent_app_date] => 2013-11-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 8 [patent_figures_cnt] => 8 [patent_no_of_words] => 14284 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14073386 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9704100 [patent_doc_number] => 08829164 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2014-09-09 [patent_title] => 'Anti-ron antibodies' [patent_app_type] => utility [patent_app_number] => 14/070070 [patent_app_country] => US [patent_app_date] => 2013-11-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 19 [patent_figures_cnt] => 23 [patent_no_of_words] => 30216 [patent_no_of_claims] => 11 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 114 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14070070 [rel_patent_id] =>[rel_patent_doc_number] =>)